Cowen & Co. Believes Amicus (FOLD) Won’t Stop Here
In a report issued on October 12, Ritu Baral from Cowen & Co. maintained a Buy rating on Amicus (FOLD), with a price target of $31.00. The company’s shares closed last Friday at $17.17, close to its 52-week high of $17.67.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 13.1% and a 48.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amicus with a $23.67 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.67 and a one-year low of $6.25. Currently, Amicus has an average volume of 2.03M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.